(CercleFinance.com) – Sanofi announces a collaboration with Teva to co-develop and co-market TEV’574, currently in phase IIb clinical trials for the treatment of ulcerative colitis and Crohn’s disease, two inflammatory bowel diseases .
Under the new agreement, Teva will receive an upfront payment of €469 million and up to €940 million in milestone payments, depending on the achievement of development and commercialization targets.
The two companies will share global development expenses, as well as net profits and losses in major markets. In other markets, royalty agreements will be put in place.
Sanofi will lead the development activities applicable to the phase III program, and the two groups will share marketing in different regions of the world. The first results of the program should be available in 2024.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
